Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in Cancer SYDNEY, Nov. 5, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an
Presentations to Explore Paxalisib's Differentiated Tumor and Immune Reprogramming ActivitySYDNEY, Nov. 2, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an
Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to KaziaSYDNEY, Sept. 22, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently existSYDNEY, Sept. 9, 2026 /CNW/ -- Kazia Therapeutics
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor ActivityThree-Arm Expansion of the Ongoing TNBC Trial Will Evaluate Paxalisib
Company to host a corporate update call Tuesday, September 1st at 8:00am ETSYDNEY, Aug. 31, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused
SYDNEY, Aug. 28, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer
SYDNEY, Aug. 27, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer
Durable Complete Metabolic Response Ongoing Since November 2025All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51%
SYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused biotechnology company developing therapies that reprogram cancer biology, restore anti-tumor immunity and
DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability DataSYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the
